Literature DB >> 443651

Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU).

J R Durant, M J Norgard, T M Murad, A A Bartolucci, K H Langford.   

Abstract

Ten patients developed pulmonary fibrosis after bischloroethylnitrosourea (BCNU) therapy for malignancy. This was lethal in seven patients, four of whom had no evidence of tumor at autopsy. Presenting symptoms were either the insidious onset of cough and dyspnea or the sudden onset of respiratory failure. Physical findings were unremarkable. Chest roentgenogram usually showed interstitial infiltrates. Pulmonary function studies showed resting hypoxia with diffusion and restrictive defects. This complication of therapy does not appear to be dose related and may be made more likely by the concomitant administration of cyclophosphamide. Prednisone therapy did not benefit most patients. The literature and the implications of the use of BCNU alone or in combination are reviewed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 443651     DOI: 10.7326/0003-4819-90-2-191

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  15 in total

1.  Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.

Authors:  Andrew A Lane; Philippe Armand; Yang Feng; Donna S Neuberg; Jeremy S Abramson; Jennifer R Brown; David C Fisher; Ann S LaCasce; Eric D Jacobsen; Steven L McAfee; Thomas R Spitzer; Arnold S Freedman; Yi-Bin Chen
Journal:  Leuk Lymphoma       Date:  2012-01-03

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  High dose BCNU with autologous bone marrow rescue in the treatment of recurrent malignant gliomas.

Authors:  J E Mortimer; J S Hewlett; J Bay; R B Livingston
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

5.  Status spongiosus in the course of treatment of malignant gliomas.

Authors:  M Poisson; J J Hauw; R Mashaly; C Duyckaerts; R Escourolle
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130

6.  Intensive chemotherapy with autologous bone marrow rescue for recurrent malignant gliomas.

Authors:  K Nomura; T Watanabe; O Nakamura; M Ohira; S Shibui; K Takakura; Y Miki
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

Review 7.  Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications.

Authors:  D S Klein; P R Wilds
Journal:  Can Anaesth Soc J       Date:  1983-07

8.  Fatal pulmonary toxic effects of lomustine.

Authors:  R G Dent
Journal:  Thorax       Date:  1982-08       Impact factor: 9.139

9.  Radiologic evaluation of pulmonary injury following carmustine- and cyclophosphamide-based preparative regimen for autologous peripheral blood stem cell transplantation in children.

Authors:  Yu Jin Kim; Woo Sun Kim; Young Hun Choi; Jung-Eun Cheon; Jung Yoon Choi; Hyoung Jin Kang; Ji-Eun Park; Young Jin Ryu; In-One Kim
Journal:  Pediatr Radiol       Date:  2018-08-18

Review 10.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.